Why Are Barrette Sales Spiking? Thank Ozempic.
Hair loss is on the rise, in step with GLP-1 drug usage and general stress levels, and causing a measurable shift in clip preferences.
Innovent’s obesity drug data in adolescents; Everest gets rights to PCSK9 inhibitor
Plus, news about BioCryst, Cycle Pharma, Applied Therapeutics, Contineum Therapeutics, Juncell Therapeutics, Cosette and Mayne Pharma: 📊 Innovent’s mazdutide shows early promise in adolescents: The injected GLP-1/glucagon agonist allowed body weight and BMI reductions …
STAT+: Pharmalittle: We’re reading about FDA staff fears, a Lilly weight loss drug and much more
And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda is still coming together. We plan to catch up on our reading, spend time with one of the short people and observe an […]
Analysis-Alzheimer’s Drug Hunt Learns From Cancer Fight’s Multi-Target Playbook
By Deena BeasleyDec 12 (Reuters) – Alzheimer’s trials testing Novo Nordisk’s blockbuster GLP-1 drug semaglutide, despite their failure, underscore…
GLP-1s Cut Dementia Risk vs DPP-4 in Dialysis Patients
Patients with diabetes undergoing hemodialysis who initiate GLP-1 agonists have an 18% lower risk for incident dementia than those who initiate DPP-4 inhibitors. Medscape Medical News
JCM, Vol. 14, Pages 8792: Functional and Aesthetic Periorbital, Ocular Adnexal and Ocular Surface Changes Linked to GLP-1 Receptor Agonists
JCM, Vol. 14, Pages 8792: Functional and Aesthetic Periorbital, Ocular Adnexal and Ocular Surface Changes Linked to GLP-1 Receptor Agonists Journal of Clinical Medicine doi: 10.3390/jcm14248792 Authors: Dimitrios Kapantais Panagiotis Tsoutsanis Background/Objectives: Glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonists have revolutionised obesity and type 2 diabetes management through effective weight loss and […]
Nature Metabolism: Alcohol addiction and liver damage are driven by endogenous fructose metabolism
A new paper in Nature Metabolism offered huge validation to the emerging theory that “fructose is the primary driver of metabolic syndrome”. The Paper: Identification of a common ketohexokinase-dependent link driving alcohol intake and alcohol-associated liver disease in mice TL;DR We usually think of alcohol and sugar as separate, but we’ve also had decades of […]
Antioxidants, Vol. 14, Pages 1490: Antidiabetic Agents as Antioxidant and Anti-Inflammatory Therapies in Neurological and Cardiovascular Diseases
Antioxidants, Vol. 14, Pages 1490: Antidiabetic Agents as Antioxidant and Anti-Inflammatory Therapies in Neurological and Cardiovascular Diseases Antioxidants doi: 10.3390/antiox14121490 Authors: Snehal Raut Luca Cucullo Neurological disorders and cardiovascular disease (CVD) remain leading causes of global morbidity and mortality and often coexist, in part through shared mechanisms of chronic inflammation and oxidative stress. Neuroinflammatory signaling, […]
Oh no, Ozempic! Eli Lilly’s New Weight-Loss Drug KOs Rival Treatments
How do you swear in Danish? Our AI chatbots are much too polite to help us out here, but we suspect you would have heard them all echoing outside the offices of Novo Nordisk yesterday. Eli Lilly, its leading rival in the burgeoning weight-loss drug market, announced trial results for an experimental obesity drug that […]
GLP-1 Drugs Tirzepatide and Semaglutide Provide Protection for Heart Health
submitted by /u/MassGen-Research [link] [comments]